A presumed case of Darbepoetin‐induced myocardial infarction in the patient with MDS‐RARS
Abstract Our case is only the 2nd such reported case of atherothrombosis from ESAs and highlights the increased risk of cardiovascular events in patients receiving erythropoietin‐stimulating agents specially patients with underlying MDS where targeting a lower hemoglobin goal and optimizing other ca...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-04-01
|
Series: | Clinical Case Reports |
Subjects: | |
Online Access: | https://doi.org/10.1002/ccr3.2728 |